文献速递白血病MDS 与骨髓增殖性肿瘤

在TP53-Y220C突变急性髓系白血病中恢复p53野生型构象

Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia.
PubMed 文献 · Blood · 2025-01-01

本文研究小分子PC14586(rezatapopt)在TP53-Y220C突变急性髓系白血病中恢复p53野生型构象的作用。PC14586可恢复p53野生型构象并激活p53转录靶点,但凋亡诱导有限;MDM2和XPO1降低p53转录活性,联合抑制可完全恢复;联合维奈克拉可充分补偿凋亡缺陷并延长异种移植生存。

要点

  • PC14586可恢复p53-Y220C为野生型构象并激活转录靶点,但凋亡诱导有限。
  • MDM2和XPO1降低PC14586激活的p53转录活性,抑制两者可完全恢复。
  • 维奈克拉联合PC14586可诱导大量细胞死亡并延长TP53-Y220C AML异种移植生存。

核心结论

  • PC14586可恢复p53野生型构象并激活转录靶点,但凋亡诱导有限。
  • MDM2和XPO1降低p53转录活性,抑制MDM2和/或XPO1可完全恢复。
  • 维奈克拉联合PC14586可充分补偿凋亡缺陷并延长TP53-Y220C AML异种移植生存。
  • 已启动PC14586在TP53-Y220C AML/MDS的临床试验(NCT06616636)。

研究设计与样本

  • 研究为体外细胞实验和体内异种移植模型研究,使用TP53-Y220C突变急性髓系白血病细胞。
  • PC14586(rezatapopt)为设计结合p53-Y220C结构口袋的小分子。

主要发现

  • PC14586将p53-Y220C转化为p53野生型构象并激活p53转录靶点,但在TP53-Y220C AML中诱导有限或无凋亡。
  • PC14586激活的构象p53野生型诱导MDM2和核输出蛋白1(XPO1),降低p53转录活性;抑制MDM2和/或XPO1可完全恢复转录活性。
  • p53野生型蛋白可结合BCL-2并与BAX竞争BH3结合口袋,还结合BCL-xL和MCL-1;但PC14586激活的构象p53野生型未检测到此类结合。
  • 维奈克拉抑制BCL-2/BAX相互作用可充分补偿该缺陷,在体外诱导AML细胞及干/祖细胞大量死亡,并在体内延长TP53-Y220C AML异种移植生存。

临床怎么用

  • 原文结论提出优化TP53突变白血病凋亡诱导的策略,包括联合抑制MDM2和/或XPO1以及联合维奈克拉。
  • 原文指出PC14586在TP53-Y220C AML/MDS的临床试验已启动(NCT06616636)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

TP53-Y220C is a recurrent hot spot mutation in cancers and leukemias. It is observed predominantly in acute myeloid leukemia (AML)/myelodysplastic syndromes among hematological malignancies and is associated with poor outcome. The mutation creates a structural pocket in the p53 protein. PC14586 (rezatapopt) is a small molecule designed to bind to this pocket and thus restore a p53 wild-type (p53-WT) conformation. We demonstrate that PC14586 converts p53-Y220C into a p53-WT conformation and activates p53 transcriptional targets but surprisingly induces limited/no apoptosis in TP53-Y220C AML. Mechanistically, MDM2 induced by PC14586-activated conformational p53-WT and the nuclear exporter exportin 1 (XPO1) reduce the transcriptional activities of p53, which are fully restored by inhibition of MDM2 and/or XPO1. Importantly, p53-WT protein can bind to B-cell lymphoma 2 (BCL-2), competing with BCL-2-associated X protein (BAX) in the BH3 binding pocket of BCL-2, and also binds to BCL-xL and myeloid cell leukemia 1 (MCL-1). However, such binding by PC14586-activated conformational p53-WT is not detected. Pharmacological inhibition of the BCL-2/BAX interaction with venetoclax fully compensates for this deficiency, induces massive cell death in AML cells and stem/progenitor cells in vitro, and prolongs survival of TP53-Y220C AML xenografts in vivo. Collectively, we identified transcription-dependent and -independent mechanisms that limit the apoptogenic activities of reactivated conformational p53-WT and suggest approaches to optimize apoptosis induction in TP53-mutant leukemia. A clinical trial of PC14586 in TP53-Y220C AML/myelodysplastic syndromes has recently been initiated. This trial was registered at www.ClinicalTrials.gov as #NCT06616636.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Carter BZ, Mak PY, Ayoub E, et al. Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia. Blood. 2025. PMID: 40608889. doi:10.1182/blood.2025028935

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。